Investigational drugs in sickle cell anemia

Bibliography

• Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle cell disease. Am J Genet 2001;151:839-45
   Google Scholar
• Gladwin M, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008;359:2254-65
   PubMed Web of Science ®Google Scholar
• Johnson C, Tellen MJ. Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. Haematologica 2008;93:481-5
   PubMed Web of Science ®Google Scholar
• Testa U. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol 2008;88:505-28
   PubMed Web of Science ®Google Scholar
• Fathallah H, Atweh G. Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematology 2006;1:58-62
   Google Scholar
• Trompeter S, Roberts I. Heamoglobin F modulation in childhood sickle cell disease. Br J Hematol 2008;144:308-16
   PubMed Web of Science ®Google Scholar
• Serjeant G. Geographic heterogeneity of sickle cell disease. In: Disorders of Hemoglobin. Steinberg MH, Forget BG, Higgs DR, Nagel RL (editors). Cambridge University Press, Cambridge, UK 2001. p. 895-7
   Google Scholar
• Farber MB, Koshy M, Kinney TR. Cooperative study of sickle cell disease: demographic and socioeconomic characteristics of patients and families with sickle cell disease. J Chronic Dis 1985;38:495-505
   PubMedGoogle Scholar
• Letvin NL, Linch DC, Beardsley GP. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 1984;310:869-73
   PubMed Web of Science ®Google Scholar
• Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 1989;32:104-11
   PubMed Web of Science ®Google Scholar
• Fibach E, Burke KP, Schechter AN, Hydroxyurea increases fetal hemoglobin in cultured erythroid cells derived from normal individuals and patients with sickle cell anemia or beta-thalassemia. Blood 1983;81:1630-5
   Google Scholar
• Kumkhaek C, Taylor J, Zhu J, Fetal hemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anemia. Br J Haematol 2008;141:254-9
   PubMed Web of Science ®Google Scholar
• Cokic V, Andric S, Stojilkovic S, Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood 2007;111:1117-23
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin M, Moore R, Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-22
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Barton F, Castro O, Effect of hydroxyurea on morbidity and mortality in adult sickle cell anemia. JAMA 2003;289:1645-51
   PubMed Web of Science ®Google Scholar
• Hankins J, Aygun B. Pharmacotherapy in sickle cell disease-state of the art and future prospects. Br J Haematol 2009;145:1365-77
   Google Scholar
• Ballas SK, Marcolina MJ, Dover GJ, Erythropoietic activity in patients with sickle cell anemia before and after treatment with hydroxyurea. Br J Haematol 1999;105:491-6
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Lu ZH, Barton FB, Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood 1997;89:1078-88
   PubMed Web of Science ®Google Scholar
• Ballas SK, Barton FB, Waclawiw MA, Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes 2006;4:1-8
   PubMedGoogle Scholar
• Saunthararajah Y, Lavelle D, Desimone J, DNA hypo-methylating agents and sickle cell disease. Br J Hematol 2004;126:629-36
   PubMed Web of Science ®Google Scholar
• Desimone J, Heller P, Hall L, 5-azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. PNAS 1982;78:4428-231
   Google Scholar
• Ley TJ, Desimone J, Noguchi CT, 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983;62:370-80
   PubMed Web of Science ®Google Scholar
• Dover GJ, Carache S, Boyer SH, 5-Azacytidine increases HgF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens. Blood 1985;66:527-32
   PubMed Web of Science ®Google Scholar
• Fathallah H, Atweh GF. DNA hypomethylation therapy for hemoglobin disorders: molecular mechanisms and clinical applications. Blood Rev 2006;20:227-34
   PubMed Web of Science ®Google Scholar
• Koshy M, Dorn L, Bressler L, 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000;96:2379-84
   PubMed Web of Science ®Google Scholar
• Desimone J, Koshy M, Dorn L, Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002;99:3905-8
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y, Hillery CA, Lavelle D, Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003;102:3865-70
   PubMed Web of Science ®Google Scholar
• Perrine SP, Ginder GD, Faller DV, A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993;328:129-31
   PubMedGoogle Scholar
• Atweh GF, Sutton M, Nassif I, Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999;93:1790-7
   PubMed Web of Science ®Google Scholar
• Fathallah H, Weinberg RS, Galperin Y, Role of epigenetic modification in normal globin gene regulation and butyrate mediated induction of fetal hemoglobin. Blood 2007;110:3391-7
   PubMed Web of Science ®Google Scholar
• Dover GJ, Brusilow S, Carache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994;84:339-43
   PubMed Web of Science ®Google Scholar
• Resar LM, Segal JB, Fitzpatrick LK. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low dose sodium phenylbutyrate therapy. J Pediatr Hematol Oncol 2002;24:737-41
   PubMed Web of Science ®Google Scholar
• Selby R, Nisbet-Brown E, Basran RK, Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood 1997;90:891-3
   PubMed Web of Science ®Google Scholar
• Ronndahl G, Monkemeyer S, Schulze S, Novel valproic acid derivatives with hemoglobin F inducing activity. Am J Hematol 2006;81:374-6
   PubMed Web of Science ®Google Scholar
• Al-Khatti A, Veith RW, Papayannopoulou T, Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. N Engl J Med 1987;317:415-20
   PubMed Web of Science ®Google Scholar
• Lavelle D, Molokie R, Ducksworth J, Effects of hydroxyurea, stem cell factor and erythropoietin in combination on fetal hemoglobin in the baboon. Exp Hematol 2001;29:156-62
   PubMed Web of Science ®Google Scholar
• Goldberg MA, Brugnara C, Dover GJ, Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 1990;323:366-72
   PubMed Web of Science ®Google Scholar
• Rivera A, Jarolim P, Brugnara C. Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood 2002;99:357-63
   PubMed Web of Science ®Google Scholar
• El-Hazmi MA, Al-Momen A, Warsy AS, On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. Acta Haematol 1995;94:128-34
   PubMed Web of Science ®Google Scholar
• Aerbajinai W, Gao Z, Zhu J, Thalidomide induces gamma-globin gene expression through reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 2007;110:2864-71
   PubMed Web of Science ®Google Scholar
• Moutouh-De Parseval LA, Verhelle D, Glezer E, Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ stem cells. J Clin Invest 2008;118:248-58
   PubMed Web of Science ®Google Scholar
• Romero J, Suzuka S, Nagel RL, Arginine supplementation of sickle transgenic mice reduces red cell density and gardos channel activity. Blood 2002;99:1103-6
   PubMed Web of Science ®Google Scholar
• Nagel RL, Vichinsky E, Shah M, F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double blind study. Blood 1993;81:9-14
   PubMed Web of Science ®Google Scholar
• Singh P, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev 2007;4:CD003426
   PubMedGoogle Scholar
• Brugnara C, Gee B, Armsby CC, Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996;97:1227-34
   PubMed Web of Science ®Google Scholar
• Ataga KI, Smith WR, De Castro LM, Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008;111:3991-7
   PubMed Web of Science ®Google Scholar
• Defranceschi L, Beuzard Y, Jouault H, Modulation of erythrocyte potassium chloride cotransport, potassium content and density of magnesium dietary intake in transgenic SAD mice. Blood 1996;88:2738-44
   PubMed Web of Science ®Google Scholar
• Defranceschi L, Bachir D, Galacteros F, Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997;100:1847-52
   PubMed Web of Science ®Google Scholar
• Hankins JS, Wynn LW, Brugnara C, Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anemia. Br J Hematol 2007;140:80-5
   PubMed Web of Science ®Google Scholar
• De Franceschi L, Bachir D, Galacteros F, Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Hematol 2000;108:284-9
   PubMed Web of Science ®Google Scholar
• Lee M, Rosenzweig EB, Cairo MS. Pulmonary hypertension in sickle cell disease. Clin Adv Hematol Oncol 2007;5:645-54
   PubMedGoogle Scholar
• Wood KC, Granger DL. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol Physiol 2007;34:926-32
   PubMed Web of Science ®Google Scholar
• Cosby K, Partovi KS, Crawford JH, Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003;9:1498-505
   PubMed Web of Science ®Google Scholar
• Kato GJ, Gladwin MT. Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy. JAMA 2008;300:2638-46
   PubMed Web of Science ®Google Scholar
• Morris CR, Kuypers FA, Larkin S, Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Hematol 2000;111:498-500
   PubMed Web of Science ®Google Scholar
• Morris CR, Morris SMJr, Hagar W, Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-9
   PubMed Web of Science ®Google Scholar
• Styles LA, Kuypers K, Kesler K, Arginine therapy does not benefit children with sickle cell anemia – results of the CSCC clinical trial consortium multi-institutional study. Blood 2007:110; ASH abstract 2252
   Google Scholar
• Lopez BL, Kreshak AA, Morris CR, L-arginine levels are diminished in adult vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol 2003;120:532-4
   PubMed Web of Science ®Google Scholar
• Little JA, Hauser KP, Martyr SE, Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Hematol 2009;82:315-21
   PubMed Web of Science ®Google Scholar
• Kato G. Novel small molecule therapeutics for sickle cell disease: nitric oxide, carbon monoxide, nitrite and apolipoprotein A-1. Hematology Am Soc Hematol Educ Program 2008;186-92
   PubMedGoogle Scholar
• Lopez BL, Davis-Moon L, Ballas SK, Sequential nitric oxide measurements during the emergency department treatment of acute vaso-occlusive sickle cell crisis. Am J Hematol 2000;64:15-9
   PubMed Web of Science ®Google Scholar
• Weiner DL, Hibberd PL, Betit P, Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 2004;289:1136-42
   Web of Science ®Google Scholar
• Mack K, Mcgowan V, Tremonti C, Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. Br J Hematol 2008;142:971-8
   PubMed Web of Science ®Google Scholar
• Machado RF, Martyr S, Kato GJ, Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005;130:445-53
   PubMed Web of Science ®Google Scholar
• Sabaa N, De Francheschi L, Bonnin P, Endothelin receptor antagonism prevents hypoxia induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest 2008;118:1924-33
   PubMed Web of Science ®Google Scholar
• Benza RL. Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment. Lung 2008;186:247-54
   PubMed Web of Science ®Google Scholar
• Katusic ZS, D'Uscio LV, Cao S, Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci 2009;30:48-54
   PubMed Web of Science ®Google Scholar
• Solovey A, Kollander R, Shet A, Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004;104:840-6
   PubMed Web of Science ®Google Scholar
• Solovey AA, Solovey AN, Harkness J, Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 2001;97:1937-41
   PubMed Web of Science ®Google Scholar
• Adam-Graves P, Kedar A, Koshy M, RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood 1997;90:2041-6
   PubMed Web of Science ®Google Scholar
• Orringer EP, Casella JF, Ataga KI, Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA 2001;286:2099-106
   PubMed Web of Science ®Google Scholar
• Ballas SK, Files B, Luchtman-Jones L, Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin 2004;28:85-102
   PubMed Web of Science ®Google Scholar
• Imayu EW, Turner EA, Asakura T. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Br J Hematol 2002;118:337-43
   PubMed Web of Science ®Google Scholar
• Imayu EW, Turner EA, Asakura T. Niprisan (Nix-0699) improves the survival rate of transgenic sickle cell mice under acute hypoxic conditions. Br J Hematol 2003;122:1001-8
   PubMed Web of Science ®Google Scholar
• Wambebe C, Khamofu H, Momoh JA, Double blind, placebo controlled, randomized cross-over clinical trial of NIPRISAN in patients in sickle cell disorder. Phytomedicine 2001;8:252-61
   PubMed Web of Science ®Google Scholar
• Styles LA, Schalkwijk CG, Aarsman AJ, Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood 1996;87:2573-8
   PubMed Web of Science ®Google Scholar
• Ballas SK, Files B, Luchtman-Jones L, Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome. Hemoglobin 2005;30:165-70
   Web of Science ®Google Scholar
• Matsui SM, Varki A, Embury SH, Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 2002;100:3790-6
   PubMed Web of Science ®Google Scholar
• Qari MH, Aljaouni SK, Alardawi MS, Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost 2007;98:392-6
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Takemoto CM, Keefer JR, Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatr Blood Cancer 2008;50:1006-12
   PubMed Web of Science ®Google Scholar
• Ballas SK. Corticosteroids and sickle cell disease. J Natl Med Assoc 2009;101:283
   PubMed Web of Science ®Google Scholar
• Ballas SK. Hydration of sickle erythrocytes using a herbal extract (Pfaffia paniculata) in vitro. Br J Hematol 2000;111:359-62
   PubMed Web of Science ®Google Scholar